Co-Target(s) Information

Content Navigation (  All   None )                                      
Target General Information
Co-Targets of This Target
References
Target General Information  Top
Target ID T59881 Target Info
Target Name Vasopressin V1b receptor (V1BR)
Synonyms
Vasopressin V3 receptor; Vasopressin V(1b) Receptor; VPR3; V1bR; Antidiuretic hormone receptor 1b; AVPR3; AVPR V3; AVPR V1b
    Click to Show/Hide
Target Type Successful Target
Gene Name AVPR1B
Biochemical Class GPCR rhodopsin
UniProt ID
V1BR_HUMAN
Co-Targets of This Target  Top
Co-Target Name Oxytocin receptor (OTR) Successful Target
UniProt ID OXYR_HUMAN
Gene Name OXTR
Synonyms
OT-R
    Click to Show/Hide
Representative Drug(s) Oxytocin Drug Info EC50 = 0.0046 nM Click to Show More [1]
2 SSR149415 Drug Info Ki = 1.514 nM [4]
3 ATOSIBAN Drug Info Ki = 11 nM [2]
4 Desmopressin Drug Info EC50 = 72 nM [5]
5 Mozavaptan Drug Info Ki = 660 nM [9]
Co-Target Name Vasopressin V1a receptor (V1AR) Successful Target
UniProt ID V1AR_HUMAN
Gene Name AVPR1A
Synonyms
Vascular/hepatic-type arginine vasopressin receptor; V1aR; V1a vasopressin receptor; Antidiuretic hormone receptor 1a; AVPR1; AVPR V1a
    Click to Show/Hide
Representative Drug(s) ATOSIBAN Drug Info Ki = 0.15 nM Click to Show More [2]
2 Oxytocin Drug Info EC50 = 0.18 nM [1]
3 SSR149415 Drug Info Ki = 22 nM [7]
4 Desmopressin Drug Info Ki = 62.4 nM [8]
5 Mozavaptan Drug Info Ki = 195 nM [9]
Co-Target Name Vasopressin V2 receptor (V2R) Successful Target
UniProt ID V2R_HUMAN
Gene Name AVPR2
Synonyms
Renal-type arginine vasopressin receptor; DIR3; DIR; Antidiuretic hormone receptor; AVPR V2; ADHR
    Click to Show/Hide
Representative Drug(s) Desmopressin Drug Info EC50 = 0.2 nM Click to Show More [3]
2 Oxytocin Drug Info EC50 = 7.3 nM [5]
3 Mozavaptan Drug Info Ki = 9.42 nM [6]
4 SSR149415 Drug Info Ki = 290 nM [10]
5 ATOSIBAN Drug Info Ki = 330 nM [2]
References  Top
REF 1 Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors. Bioorg Med Chem. 2019 Aug 1;27(15):3358-3363.
REF 2 The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
REF 3 Discovery of Potent, Selective, and Short-Acting Peptidic V 2 Receptor Agonists. J Med Chem. 2019 May 23;62(10):4991-5005.
REF 4 The characterization of a novel V1b antagonist lead series. Bioorg Med Chem Lett. 2011 Jan 1;21(1):92-6.
REF 5 New, potent, and selective peptidic oxytocin receptor agonists. J Med Chem. 2014 Jun 26;57(12):5306-17.
REF 6 Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template. J Med Chem. 2000 Nov 16;43(23):4388-97.
REF 7 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
REF 8 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
REF 9 Selective fluorescent nonpeptidic antagonists for vasopressin V? GPCR: application to ligand screening and oligomerization assays. J Med Chem. 2012 Oct 25;55(20):8588-602.
REF 10 Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3828-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.